Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis
- Conditions
- Psoriasis
- Interventions
- Other: Blood samples
- Registration Number
- NCT04308616
- Lead Sponsor
- University Hospital, Tours
- Brief Summary
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis.
Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time.
A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
- Detailed Description
Squamous Cell Carcinoma Antigen (SCCA) contributes to the pathogenesis of psoriasis by inhibiting cell apoptosis, exacerbating epidermal hyperplasia and skin inflammation. Three studies have shown a correlation between blood levels of SCCA and the severity of psoriasis.
Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation). The PASI (Psoriasis Assessment Severity Index, minimum score 0, maximum 72) is the most widely used. It suffers from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. This PASI score was "unavoidable" in the international clinical studies used to obtain marketing authorisation for medicines. The PGA (Physician global assessment) is simpler and less time-consuming, ranging from 0 to 4, but is not very discriminating. More recently, a "Simplified Psoriasis Index" (proSPI) health professional score has been developed, which correlates well with PASI for the severity component of psoriasis and with quality of life for the psychological component of the disease. It is less time-consuming to establish than PASI, but suffers like all clinical scores from a problem of inter- and intra-observer reproducibility.
A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 51
- Age ≥ 18 years old
- Patient with skin psoriasis (new and untreated or being treated, flare-up or stable, possibly bleached)
- Requiring a blood sample for disease or treatment monitoring
- History of invasive mucosal squamous cell carcinoma, or squamous cell carcinoma of the skin with lymph node or visceral recurrence.
- Patient under guardianship or curatorship
- Opposition to participation in the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Psoriasis Blood samples Patients with psoriasis
- Primary Outcome Measures
Name Time Method SCCA blood concentration Baseline, 3 months and 6 months SCCA blood concentration will be measured at each visit
- Secondary Outcome Measures
Name Time Method Assess correlations between SCCA blood concentration and proSPI severity score Baseline, 3 months and 6 months proSPI severity score (0-50) will be evaluated at each visit
Assess correlations between SCCA blood concentration and neutrophil/lymphocyte ratio Baseline, 3 months and 6 months neutrophil/lymphocyte ratio will be measured at each visit
Assess correlations between SCCA blood concentration and proSPI psychosocial score Baseline, 3 months and 6 months proSPI psychosocial score (0-10) will be evaluated at each visit
Assess correlations between SCCA blood concentration and proSPI treatment score Baseline, 3 months and 6 months proSPI treatment score (0-10) will be evaluated at each visit
Assess correlations between SCCA blood concentration and C reactive protein (CRP) Baseline, 3 months and 6 months CRP will be measured at each visit
Trial Locations
- Locations (1)
Dermatology Service, University Hospital, Tours
🇫🇷Tours, France